Phase I Study of Docetaxel, Prednisone and Pazopanib in Men With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and Poor-Risk Factors

Trial Profile

Phase I Study of Docetaxel, Prednisone and Pazopanib in Men With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and Poor-Risk Factors

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Pazopanib (Primary) ; Docetaxel; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 03 Feb 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 01 Apr 2014 The study phase was changed from I/II to phase I. Planned patient number was changed from 122 to 36 due to change in the treatment protocol according to the ClinicalTrials.gov record. Endpoints were modified according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top